Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen

BACKGROUND: Triple-negative (TN) breast cancers exhibit major initial responses to neoadjuvant chemotherapy, but generally have a poor outcome. Because of the lack of validated drug targets, chemotherapy remains an important therapeutic tool in these cancers. METHODS: We report the survival of two c...

Descripción completa

Detalles Bibliográficos
Autores principales: Giacchetti, S, Porcher, R, Lehmann-Che, J, Hamy, A-S, de Roquancourt, A, Cuvier, C, Cottu, P-H, Bertheau, P, Albiter, M, Bouhidel, F, Coussy, F, Extra, J-M, Marty, M, de Thé, H, Espié, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960631/
https://www.ncbi.nlm.nih.gov/pubmed/24569467
http://dx.doi.org/10.1038/bjc.2014.81

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960631/
https://www.ncbi.nlm.nih.gov/pubmed/24569467
http://dx.doi.org/10.1038/bjc.2014.81

Ejemplares similares